Matt Cutts
Angel Investor
San Francisco, United States
Matt Cutts is a seed investor in San Francisco focused on SaaS and Health Care. Matt Cutts joined Google as a Software Engineer in January 2000. Before Google, he was working on his Ph.D. in computer graphics at the University of North Carolina at Chapel Hill. He has an M.S. from UNC-Chapel Hill, and B.S. degrees in both mathematics and computer science from the University of Kentucky.Matt wrote SafeSearch, which isGoogle's family filter. In addition to his experience at Google, Matt held a top-secret clearance while working for the Department of Defense, and he's also worked at a game engine company. He claims that Google is the most fun by far.Matt talks about webmaster-related issues on his
- Total investments:
- 11
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Matt Cutts invests in
Stages Matt Cutts invests in
Countries Matt Cutts invests in
Round sizes
Round size
- Seed
- $493k–$2.8M
Investment Focus
Industry
- SaaS 3 (27%)
- Health Care 3 (27%)
- Medical 2 (18%)
- Software 2 (18%)
- E-Commerce 2 (18%)
Stage
- Seed 8 (73%)
- Angel 1 (9%)
- Series A 1 (9%)
Country
- United States 7 (64%)
- Canada 1 (9%)
- Mexico 1 (9%)
- Singapore 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Unima
|
Unima is decentralizing rapid testing across industries by taking diagnostics out of the lab to the place these are needed the most to secure a timely diagnostic for everyone, anywhere.Unima is solving is the centralization of lab testing, which limits the access to a timely diagnostic for billions. Current technology for diagnostics is veryprecise and can detect almost any disease known, but the problem is these require labs with expensive equipment and specialized technicians making lab testing impossible to scale up to provide universal and timely access to diagnostics.To solve this problem Unima developed Find, a rapid testing technology platform for real time diagnostics which allows anyone to diagnose a disease directly where it is needed, without using lab equipment, with results in 15 minutes or less and at a very low cost. With Find anyone can have access to a timely diagnostic even in the most remote areas of the world.The Find platform uses shark antibodies modified with genetic engineering to detect disease biomarkers in blood, saliva, urine or water samples. These shark antibodies are used in microfluidic cards and generate a visual reactions when in contact with specific biomarkers of the disease to be tested. Then to evaluate the result of the test, a picture of the testing card is taken with the proprietary Xplora smartphone app which runs image analysis process and neural network algorithms to generate an inmediate result. Then this result,along with contextual information like geolocation, date and time, is sent to a cloud server where it can be used for real time disease tracking. | $1.9M / Seed / Mar 24, 2019 | |
Meter Feeder
|
Meter Feeder's mission to provide a low cost payment and enforcement solution for small to mid-sized governments. A fast set up process and geolocation get new users paid and on their way fast. MeterFeeder works with customers' current infrastructure. Users don't need to purchase any new meters or kiosks, growing the base of peoplemore willing to pay via electronic payments. | $493K / Seed / Apr 13, 2017 | |
X-ZELL
|
X-ZELL’s vision is to save lives by identifying clinically significant cancers early, when there is still time to act and take charge of our health.X-ZELL first made headlines in 2017 when it found a way to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in a small, 10mL blood sample. Known to be powerful biomarkers forthe early detection of aggressive cancers, tCEC were long considered ‘undetectable’ in clinical routine. X-ZELL overcame the impasse by developing a platform technology that is capable of detecting a single tCEC among five billion healthy blood cells and analysing it using Artificial Intelligence – making for an affordable, non-invasive solution with maximum scalability. Less than a year after that breakthrough, X-ZELL was able to present the world’s first tCEC-based blood test for the early detection of clinically significant prostate cancer – X-ZELL™ Prostate. But one cancer is not enough. X-ZELL’s ambition is to make accurate, affordable tCEC screening available to everyone, everywhere – which is why additional tests for common cancers such as breast, ovarian, colon and lung have already gone into pre-development, with more to come. They all feed into the creation of an AI-driven general screening test that will be able to scrutinise our blood for atypical cells and analyse them on-screen – allowing physicians to manage our health proactively instead of just responding to a disease. | $1.3M / Seed / Mar 22, 2016 | |
Nuzzel
|
Nuzzel is a professional news discovery service used by many of the top influencers in media, technology, and finance.Nuzzel was named one of the best apps of the year by Google Play, the New York Times, Fast Company, and Time Magazine.Nuzzel is backed by top Silicon Valley investors including Andreessen Horowitz, CRV, Homebrew, LowercaseCapital, Uncork Capital, Marc Benniof, and Max Levchin. | $1.7M / Seed / Nov 19, 2015 | |
Taplytics
|
Developer of a SaaS customer engagement platform designed for the world's leading enterprise brands to improve and personalize their apps, websites, and customer communication channels. The Company's platform unifies the digital customer journey, product optimization, and marketing automation in a single, AI driven application. Thisempowers modern engineering and marketing teams to create robust customer experiences, using contextual data and AI orchestration to optimize customer engagement, conversion and revenue. | $2.4M / Seed / May 20, 2015 | |
PlanGrid
|
PlanGrid provides a cloud-based construction document collaboration platform that allows plans, markups, photos, and reports to be instantaneously shared with everyone on a construction project. Its platform lets contractors and architects collaborate from their desktop or mobile devices across all their project plans, specifications, photos, RFIs,and punchlists. Major construction firms use the platform of PlanGrid. Kenny Stone, Ralph Gootee, Ryan Sutton-Gee, and Tracy Young founded Loupe in 2011 that later became PlanGrid, with its headquarters in San Francisco in California. | $1.1M / Seed / May 29, 2012 | |
DrChrono
|
DrChrono's mission is to give physicians, medical groups, large practices, enterprises, and clinics a path to the future. Our goal is to give physicians an all-in-one platform. | $2.8M / Seed / Jan 26, 2012 | |
|
DrChrono
|
DrChrono's mission is to give physicians, medical groups, large practices, enterprises, and clinics a path to the future. Our goal is to give physicians an all-in-one platform. | $675K / Seed / Jul 14, 2011 | |
Goat Group
|
Goat Group is a marketplace for authentic sneakers, apparel, and accessories. | $1.6M / Angel / May 01, 2011 | |
Zencoder
|
Zencoder is web-based video encoding software as a service, designed to quickly convert any video into web and mobile compatible formats. It is for web sites and applications that accept uploaded videos and need to encode them to standard formats. | $2M / Series A / Apr 12, 2011 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Matt Cutts invest in?
Matt Cutts invests primarily in SaaS, Health Care and Medical startups, most often at Seed and Angel stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Matt Cutts's check size?
Matt Cutts typically joins rounds of $493k–$2.8M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Matt Cutts participates in.
When did Matt Cutts last invest?
The most recent investment recorded for Matt Cutts closed in Mar 2019. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
